ZTS Quote, Financials, Valuation and Earnings

Biomarin Pharmaceutical has a net margin of 28.56% compared to Zoetis's net margin of 14.23%. Zoetis's return on equity of 48% beat Biomarin Pharmaceutical's return on equity of 6.29%.

Zoetis has a consensus price target of $214.22, signalling upside risk potential of 30.4%. On the other hand Biomarin Pharmaceutical has an analysts' consensus of $98.08 which suggests that it could grow by 48%. Given that Biomarin Pharmaceutical has higher upside potential than Zoetis, analysts believe Biomarin Pharmaceutical is more attractive than Zoetis.

Zoetis has a beta of 0.889, which suggesting that the stock is 11.103% less volatile than S&P 500. In comparison Biomarin Pharmaceutical has a beta of 0.295, suggesting its less volatile than the S&P 500 by 70.544%.

Zoetis has a quarterly dividend of $0.43 per share corresponding to a yield of 1.05%. Biomarin Pharmaceutical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Zoetis pays 29.52% of its earnings as a dividend. Biomarin Pharmaceutical pays out -- of its earnings as a dividend. Zoetis's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Zoetis quarterly revenues are $2.4B, which are larger than Biomarin Pharmaceutical quarterly revenues of $745.7M. Zoetis's net income of $682M is higher than Biomarin Pharmaceutical's net income of $106.1M. Notably, Zoetis's price-to-earnings ratio is 30.88x while Biomarin Pharmaceutical's PE ratio is 39.68x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zoetis is 8.20x versus 4.73x for Biomarin Pharmaceutical. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer has a net margin of 28.56% compared to Zoetis's net margin of 25.23%. Zoetis's return on equity of 48% beat Pfizer's return on equity of 4.63%.

Zoetis has a consensus price target of $214.22, signalling upside risk potential of 30.4%. On the other hand Pfizer has an analysts' consensus of $31.86 which suggests that it could grow by 19.29%. Given that Zoetis has higher upside potential than Pfizer, analysts believe Zoetis is more attractive than Pfizer.

Zoetis has a beta of 0.889, which suggesting that the stock is 11.103% less volatile than S&P 500. In comparison Pfizer has a beta of 0.653, suggesting its less volatile than the S&P 500 by 34.739%.

Zoetis has a quarterly dividend of $0.43 per share corresponding to a yield of 1.05%. Pfizer offers a yield of 6.29% to investors and pays a quarterly dividend of $0.42 per share. Zoetis pays 29.52% of its earnings as a dividend. Pfizer pays out 436.39% of its earnings as a dividend. Zoetis's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Pfizer's is not.

Zoetis quarterly revenues are $2.4B, which are smaller than Pfizer quarterly revenues of $17.7B. Zoetis's net income of $682M is lower than Pfizer's net income of $4.5B. Notably, Zoetis's price-to-earnings ratio is 30.88x while Pfizer's PE ratio is 36.09x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zoetis is 8.20x versus 2.56x for Pfizer. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals has a net margin of 28.56% compared to Zoetis's net margin of 36.03%. Zoetis's return on equity of 48% beat Regeneron Pharmaceuticals's return on equity of 17.19%.

Zoetis has a consensus price target of $214.22, signalling upside risk potential of 30.4%. On the other hand Regeneron Pharmaceuticals has an analysts' consensus of $1,053.08 which suggests that it could grow by 47.26%. Given that Regeneron Pharmaceuticals has higher upside potential than Zoetis, analysts believe Regeneron Pharmaceuticals is more attractive than Zoetis.

Zoetis has a beta of 0.889, which suggesting that the stock is 11.103% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals has a beta of 0.084, suggesting its less volatile than the S&P 500 by 91.622%.

Zoetis has a quarterly dividend of $0.43 per share corresponding to a yield of 1.05%. Regeneron Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Zoetis pays 29.52% of its earnings as a dividend. Regeneron Pharmaceuticals pays out -- of its earnings as a dividend. Zoetis's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Zoetis quarterly revenues are $2.4B, which are smaller than Regeneron Pharmaceuticals quarterly revenues of $3.7B. Zoetis's net income of $682M is lower than Regeneron Pharmaceuticals's net income of $1.3B. Notably, Zoetis's price-to-earnings ratio is 30.88x while Regeneron Pharmaceuticals's PE ratio is 17.70x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zoetis is 8.20x versus 5.94x for Regeneron Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Vertex Pharmaceuticals has a net margin of 28.56% compared to Zoetis's net margin of 37.71%. Zoetis's return on equity of 48% beat Vertex Pharmaceuticals's return on equity of -2.89%.

Zoetis has a consensus price target of $214.22, signalling upside risk potential of 30.4%. On the other hand Vertex Pharmaceuticals has an analysts' consensus of $493.61 which suggests that it could grow by 21.8%. Given that Zoetis has higher upside potential than Vertex Pharmaceuticals, analysts believe Zoetis is more attractive than Vertex Pharmaceuticals.

Zoetis has a beta of 0.889, which suggesting that the stock is 11.103% less volatile than S&P 500. In comparison Vertex Pharmaceuticals has a beta of 0.364, suggesting its less volatile than the S&P 500 by 63.631%.

Zoetis has a quarterly dividend of $0.43 per share corresponding to a yield of 1.05%. Vertex Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Zoetis pays 29.52% of its earnings as a dividend. Vertex Pharmaceuticals pays out -- of its earnings as a dividend. Zoetis's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Zoetis quarterly revenues are $2.4B, which are smaller than Vertex Pharmaceuticals quarterly revenues of $2.8B. Zoetis's net income of $682M is lower than Vertex Pharmaceuticals's net income of $1B. Notably, Zoetis's price-to-earnings ratio is 30.88x while Vertex Pharmaceuticals's PE ratio is 25.59x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zoetis is 8.20x versus 9.93x for Vertex Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.